	US 12,188,040 B2
	Method for enhancing gene expression using AAV vector
Shin-ichi Muramatsu, Tochigi (JP); Naomi Takino, Tochigi (JP); and Mika Ito, Tochigi (JP)
Assigned to GENE THERAPY RESEARCH INSTITUTION CO., LTD., Kanagawa (JP)
Appl. No. 17/263,606
Filed by GENE THERAPY RESEARCH INSTITUTION CO., LTD., Kanagawa (JP)
PCT Filed Jul. 26, 2019, PCT No. PCT/JP2019/029356 § 371(c)(1), (2) Date Jan. 27, 2021, PCT Pub. No. WO2020/026968, PCT Pub. Date Feb. 6, 2020.
Claims priority of application No. 2018-142698 (JP), filed on Jul. 30, 2018.
Prior Publication US 2021/0292790 A1, Sep. 23, 2021
Int. Cl. A61K 47/26 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); C12N 15/90 (2006.01)

CPC C12N 15/86 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 47/26 (2013.01); C12N 7/00 (2013.01); C12N 15/907 (2013.01); C12N 2750/14143 (2013.01)]

13 Claims

1. An ex vivo or in vitro method for gene transfer, comprising:

(a) providing a composition comprising a recombinant adeno-associated virus (AAV) vector and a sugar at a concentration of at least 40 mM; and

(b) bringing the composition into contact with a culture cell in a medium comprising the sugar at a final concentration of at least 40 mM.